Walter & Keenan Financial Consulting Co. MI ADV grew its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 5.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,151 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the period. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Bristol-Myers Squibb were worth $415,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Tdam USA Inc. raised its holdings in shares of Bristol-Myers Squibb by 2.3% in the 2nd quarter. Tdam USA Inc. now owns 68,949 shares of the biopharmaceutical company’s stock valued at $3,127,000 after buying an additional 1,555 shares during the period. TD Asset Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 6.3% in the 2nd quarter. TD Asset Management Inc. now owns 700,681 shares of the biopharmaceutical company’s stock valued at $31,776,000 after buying an additional 41,450 shares during the period. Westpac Banking Corp raised its holdings in shares of Bristol-Myers Squibb by 3.0% in the 2nd quarter. Westpac Banking Corp now owns 366,109 shares of the biopharmaceutical company’s stock valued at $16,603,000 after buying an additional 10,684 shares during the period. Charter Trust Co. raised its holdings in shares of Bristol-Myers Squibb by 2.5% in the 2nd quarter. Charter Trust Co. now owns 38,416 shares of the biopharmaceutical company’s stock valued at $1,742,000 after buying an additional 938 shares during the period. Finally, Dumont & Blake Investment Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 12.7% in the 2nd quarter. Dumont & Blake Investment Advisors LLC now owns 25,666 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 2,886 shares during the period. 77.37% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently issued reports on BMY. Barclays upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $53.00 to $55.00 in a report on Friday, May 3rd. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Tuesday, May 7th. BMO Capital Markets boosted their price objective on Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Argus downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective on the stock. in a report on Monday, May 20th. Finally, JPMorgan Chase & Co. began coverage on Bristol-Myers Squibb in a report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $55.88.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini acquired 11,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was acquired at an average cost of $44.72 per share, with a total value of $491,920.00. Following the transaction, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares of the company’s stock, valued at $145,818.96. The disclosure for this sale can be found here. 0.13% of the stock is owned by corporate insiders.

NYSE BMY traded up $0.04 during trading hours on Wednesday, hitting $46.55. 4,300,156 shares of the company were exchanged, compared to its average volume of 16,761,281. The company’s 50 day simple moving average is $45.29. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $63.69. The firm has a market capitalization of $77.40 billion, a price-to-earnings ratio of 11.69, a price-to-earnings-growth ratio of 2.34 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The company had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter in the prior year, the business earned $1.01 EPS. Bristol-Myers Squibb’s revenue was up 10.0% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb Co will post 4.26 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were issued a dividend of $0.41 per share. The ex-dividend date was Wednesday, July 3rd. This represents a $1.64 annualized dividend and a yield of 3.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: Cryptocurrencies

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.